The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Novartis has announced the launch of the Lucentis® (ranibizumab) prefilled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which received European approval in October 2013, is a new way of administering...
The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients'...
Shire Pharmaceuticals has initated a voluntary recall in the United States of one batch, packaged into three lots, of VPRIV, a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for...
Novo Nordisk is increasing its drug-development capacity by investing 550 million Danish kroner ($100 million) in a new research and development facility in Bagsværd, Denmark. The purification plant will expand the company's capacity to...
UCB and Sanofi have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules that have the potential to treat a wide range of immune-mediated diseases in areas such...
Teva Pharmaceutical Industries Ltd. has formed a collaboration with the United Kingdom (UK) Government's National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI). The...
Takeda Pharmaceutical Company Limited has made organizational and reporting line changes in line with Christophe Weber's assumption as Takeda's chief operating officer (COO) as of April 1, 2014, which the company had previously announced....
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development, and commercialization of immuno-oncology therapies directed toward targets...
Amgen has appointed David Piacquad to the new position of senior vice-president, business development. Piacquad will report directly to Robert A. Bradway, chairman and chief executive officer and will be responsible for business development across...
Pfizer Inc. reports that the United States District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue patent (US Patent No. RE44,048) covering methods of treating osteoarthritis and other...
With an investment of more than EUR 500 million ($695 million) at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are...
AstraZeneca has agreed to sell its Alderley Park site in Cheshire, United Kingdom (UK) to Manchester Science Parks, a Greater Manchester-based public-private partnership and science park operator. The sale is part of AstraZeneca's...
Daiichi Sankyo Company Limited reported on March 8, 2014 that Kitasato Daiichi Sankyo Vaccine Company Limited will not be able to meet development and production capacity goals to supply H5N1 vaccines by the end of March 2014...
Almac is expanding its clinical services and technologies capabilities to include on-the-ground leadership as well as technical, project and operational resources in Asia. Almac is strengthening its Asia Pacific offerings by establishing a new...
Ranbaxy Inc. has initiated a nationwide voluntary Class II recall of atorvastatin calcium tablets, 10 mg, 90-count tablets per bottle, prescription only, based on a product complaint was received by a pharmacist who discovered an...
